Unlock the Potential of GLP-1 Analogs!
Glucagon-like peptide-1 agonist (GLP-1 agonist) is a class of drugs that reduce blood glucose and energy intake by activating the GLP-1 receptor. They mimic the actions of the endogenous incretin hormone GLP-1, which is released from the gut after eating. GLP-1 is the target of many synthetic drugs on the market, initially developed in the treatment of type II diabetes, including:
Exendin-4 (ELISA Product S-1297, Rabbit anti-Exendin-4 Product T-4844): In the brain, it increases survival of dopamine neurons and decreases apoptosis of nerve cells, improving neuroplasticity. In the liver, it decreases glucose production, while in the pancreas it promotes insulin release and beta-cell proliferation. It also regulates gastric emptying in the stomach.
Liraglutide (ELISA Product S-1502, Rabbit anti-Liraglutide Product T-4880): Reduces hunger signals in the brain. In the pancreas, it stimulates insulin release, suppressing glucagon secretion during hyperglycemia. In the stomach, it regulates gastric emptying.
Lixisenatide (ELISA Product S-1509): In the brain, it has a neuroprotective function, promoting neurogenesis and memory. In the liver, it acts in glycogen storage, while in the pancreas it acts in the formation of new beta-cells and insulin biosynthesis, decreasing beta-cell apoptosis. It is a GLP-1 receptor agonist, used to improve glycemic control in type II diabetes mellitus.
Semaglutide (ELISA Product S-1530): Reduces hunger signals in the brain and food consumption. In the pancreas, it increases insulin secretion after meals and helps reduce blood glucose levels. In the liver, it increases insulin sensitivity and reduces fat accumulation. In the stomach, it regulates gastric emptying. It is a GLP-1 receptor agonist used to improve glycemic control in Type-II diabetes mellitus.
Dulaglutide (ELISA Product S-1551): In the brain, it reduces hunger signals. It acts similarly to GLP-1, increasing the amount of insulin released by the beta cells of the pancreas and the production of glucagon released by the alpha cells of the pancreas. In the liver, it regulates glucose production, while in the stomach it regulates gastric emptying.
Tirzepatide (ELISA Product S-1552): In the brain, it reduces appetite and food consumption. It increases insulin production, lipolysis (GLP-1), cardio-protection (GLP-1) and lipogenesis (GIP) in the pancreas. It also reduces bone resorption. In the stomach, it regulates gastric emptying. It is a GLP-1 receptor agonist used to manage Type-II diabetes.
Our ELISA assays and antibodies provide accurate measurement of GLP-1 analogs levels as well as histological localization, ensuring reliable data for breakthrough diabetes and obesity treatments.
Find out more about our ELISA assays and antibodies on GLP-1 analogs and contact us at info@bma.ch
We help you keep your research moving forward!
Your BMA team
Author: Dr. Sonia Accossato
Copyright © BMA Biomedicals 2024